Compare UBER & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UBER | TXMD |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.1B | 21.4M |
| IPO Year | 2019 | 2012 |
| Metric | UBER | TXMD |
|---|---|---|
| Price | $69.29 | $1.82 |
| Analyst Decision | Buy | |
| Analyst Count | 50 | 0 |
| Target Price | ★ $98.88 | N/A |
| AVG Volume (30 Days) | ★ 15.4M | 17.8K |
| Earning Date | 11-04-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.73 | ★ 73.68 |
| EPS | ★ 1.54 | 0.02 |
| Revenue | ★ $52,017,000,000.00 | $1,761,000.00 |
| Revenue This Year | $11.06 | $207.74 |
| Revenue Next Year | $15.84 | $2.15 |
| P/E Ratio | ★ $44.96 | $90.75 |
| Revenue Growth | 18.28 | ★ 35.25 |
| 52 Week Low | $64.04 | $1.43 |
| 52 Week High | $92.92 | $2.95 |
| Indicator | UBER | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.52 | 47.98 |
| Support Level | $66.14 | $1.77 |
| Resistance Level | $72.29 | $2.16 |
| Average True Range (ATR) | 2.02 | 0.07 |
| MACD | 0.43 | 0.02 |
| Stochastic Oscillator | 63.12 | 77.78 |
Uber is a technology provider that matches riders with drivers, hungry people with restaurants and food couriers, and shippers with carriers. The firm's on-demand technology platform is currently utilized by traditional cars and autonomous vehicles, but could eventually support additional products and services, such as drone delivery or electric vertical takeoff and landing (eVTOL) technology. Uber operates in over 70 countries and has over 200 million users who order rides or food at least once a month.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.